anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The lumbar vertebra and paraspinal muscles play an important role in maintaining the stability of the lumbar spine. Therefore, the aim of this study was to investigate the relationship between paraspinal muscles fat infiltration and vertebral body related changes [vertebral bone quality (VBQ) score and Modic changes (MCs)] in patients with chronic low back pain (CLBP).
METHODS: Patients with CLBP were prospectively collected in four hospitals and all patients underwent 3.0T magnetic resonance scanning. Basic clinical information was collected, including age, sex, course of disease (COD), and body mass index (BMI). MCs were divided into 3 types based on their signal intensity on T1 and T2-weighted imaging. VBQ was obtained by midsagittal T1-weighted imaging (T1WI) and calculated using the formula: SIL1-4/SICSF. The Proton density fat fraction (PDFF) values and cross-sectional area (CSA) of paraspinal muscles were measured on the fat fraction map from the iterative decomposition of water and fat with the echo asymmetry and least-squares estimation quantitation (IDEAL-IQ) sequences and in/out phase images at the central level of the L4/5 and L5/S1 discs.
RESULTS: This study included 476 patients with CLBP, including 189 males and 287 females. 69% had no Modic changes and 31% had Modic changes. There was no difference in CSA and PDFF for multifidus(MF) and erector spinae (ES) at both levels between Modic type I and type II, all P values>0.05. Spearman correlation analysis showed that VBQ was weakly negatively correlated with paraspinal muscles CSA (all r values < 0.3 and all p values < 0.05), moderately positive correlation with PDFF of MF at L4/5 level (r values = 0.304, p values<0.001) and weakly positively correlated with PDFF of other muscles (all r values<0.3 and all p values<0.001). Multivariate linear regression analysis showed that age (β = 0.141, p < 0.001), gender (β = 4.285, p < 0.001) and VBQ (β = 1.310, p = 0.001) were related to the total PDFF of muscles. For MCs, binary logistic regression showed that the odds ratio values of age, BMI and COD were 1.092, 1.082 and 1.004, respectively (all p values <  0.05).
CONCLUSIONS: PDFF of paraspinal muscles was not associated with Modic classification. In addition to age and gender, PDFF of paraspinal muscles is also affected by VBQ. Age and BMI are considered risk factors for the MCs in CLBP patients.
After standard craniectomy (12x15cm) and dural opening, the "intervention", which is to not perform watertight duraplasty is carried out. The exposed brain parenchyma is covered with Surgicel. Usual closure is then performed.
1\. Indications. Progestin-only oral contraceptives are indicated for the prevention of pregnancy.

2\. Efficacy. If used perfectly, the first-year failure rate for progestin-only oral contraceptives is 0.5%. However, the typical failure rate is estimated to be closer to 5%, due to late or omitted pills. The following table lists the pregnancy rates for users of all major methods of contraception.

Table 2: Percentage of Women Experiencing an Unintended Pregnancy During the First Year of Typical Use and the First Year of Perfect Use of Contraception and the Percentage Continuing Use at the End of the First Year. United States.
OBJECTIVE: To evaluate the sleep pattern of children and adolescents with chronic conditions during hospitalization and correlate it with resilience, quality of life, clinical and sociodemographic data.
METHOD: Quantitative, descriptive and cross-sectional study. Data collection took place between May 2022 and January 2023, with children and adolescents with chronic conditions from two hospitals in Rio de Janeiro. The instruments used were the Actigraph, Sandra Prince-Embury's Resilience Scale for Children and Adolescents and the Pediatric Quality of Life Inventory. Data analysis involved descriptive statistics and correlation tests.
RESULTS: 40 hospitalized children and adolescents between the ages of nine and 18 took part. The results showed compromised sleep, especially in terms of duration and time awake after sleep onset. Quality of life scores were low and resilience levels were classified as medium to high. Correlations were found between resilience and sleep. In addition, sleep was influenced by diagnosis and treatment.
CONCLUSION: Children and adolescents hospitalized with chronic conditions experience significant sleep disturbances and have a low quality of life, but have satisfactory levels of resilience.
OBJECTIVES: Event-free survival has replaced overall survival as a primary end point in many recent and ongoing clinical trials. This study aims to examine the correlation between real-world event-free survival and overall survival and to assess the clinical and economic burden associated with disease recurrence among patients with resected stage II to III non-small cell lung cancer who received neoadjuvant therapy in the United States.
METHODS: This retrospective study used the Surveillance, Epidemiology, and End Results Medicare database (2007-2019) to identify patients with newly diagnosed, resected, stage II to IIIB (N2) non-small cell lung cancer who received neoadjuvant therapy. The correlation between real-world event-free survival and overall survival was assessed using the normal scores rank correlation and landmark analysis. Overall survival, all-cause health care resource use and costs, and non-small cell lung cancer-related health care resource use and costs were compared between patients with and without recurrence.
RESULTS: A total of 221 patients met the eligibility criteria (median follow-up time from neoadjuvant treatment initiation: 32.7 months). The mean age was 72.1 years, and 57.0% of patients were male. Real-world, event-free survival and overall survival are positively and significantly correlated (0.68; 95% CI, 0.52-0.79). Patients with recurrence had significantly shorter median overall survival (19.3 vs 116.9 months), 4.59 times increased risk of death (95% CI, 2.56-8.26), and significantly higher all-cause and non-small cell lung cancer-related health care resource use and costs (adjusted mean monthly costs per patient difference: $5758 and $3187, respectively [all P < .001]).
CONCLUSIONS: These findings help validate event-free survival as a clinically meaningful end point and strong predictor for overall survival and highlight the need for additional novel therapies that may delay or prevent recurrence in resectable stage II and III non-small cell lung cancer.
Subjects who meet the eligibility criteria will be randomized 1:1 to titrate to one of two dose regimens: 20 mg/day or 40 mg/day. The randomization will be stratified by the last available blood Phe concentration prior to Day 1 (600 to 900 μmol/L and \> 900 μmol/L).
A novel BC fermentation technique for controlling 3D shape, thickness and architecture of the entangled cellulose nano-fibril network is presented. The resultant nano-cellulose based structures are useful as biomedical implants and devices, are useful for tissue engineering and regenerative medicine, and for health care products. More particularly, embodiments of the present invention relate to systems and methods for the production and control of 3-D architecture and morphology of nano-cellulose biomaterials produced by bacteria using any biofabrication process, including the novel 3-D Bioprinting processes disclosed. Representative processes according to the invention involve control of the rate of production of biomaterial by bacteria achieved by meticulous control of the addition of fermentation media using a microfluidic system. In exemplary embodiments, the bacteria gradually grew up along the printed alginate structure that had been placed into the culture, incorporating it. After culture, the printed alginate structure was successfully removed revealing porosity where the alginate had been placed. Porosity and interconnectivity of pores in the resultant 3-D architecture can be achieved by porogen introduction using, e.g., ink-jet printer technology.
Leprosy is a chronic infectious disease that mainly affects the skin and peripheral nerves, it can also invade deeper tissues and organs, including mucous membranes, lymph nodes, testes, eyes, and internal organs. Severe cases can result in deformities and disabilities. We encountered the case of a 39-year-old male with unexplained fever, headache and rash. The patient's lesions were taken for histopathological examination and slit skin smear analysis. Further, the patient was detected of Mycobacterium leprae (M.leprae) nucleic acid sequences in the cerebrospinal fluid (CSF) and plasma, and M.leprae gene targets in the skin lesion tissue and blood. The patient was eventually diagnosed with multibacillary leprosy and type II leprosy reaction. These results suggest the possibility of bacteremia in patients with leprosy to some extent, and observation implies the potential invasion of CSF by M.leprae or its genetic material.
The tape will be applied in the first 24 hours postoperatively and on the 5th, 10th, 15th days of the surgery. The placebo-tape application will be applied the lumbar region in a tension-free and horizontal form, while the spine is in a neutral position without positioning the patients. After sticking, the tape will be manually activated. After the tape adheres, individuals will be asked to hold the tape for five days until the next taping.
Placebo (50 mL of 0.9% sodium chloride solution) administered intravenously (with an infusion rate of 10 mL/min), 2 times a day (with a dosing interval of 8 hours ± 30 minutes) for 5 consecutive days (Day 1, Day 2, Day 3, Day 4 and Day 5). Doses will be administered at the same time of the day (every 24 hours ± 30 minutes).
A male infant born in a tertiary maternity facility was noted to have microretrognathia, a small mouth and macroglossia at delivery. He was born limp and apnoeic and required multiple attempts at intubation before a definitive airway was eventually sited. Chest X-rays, while in the paediatric intensive care unit, demonstrated dysplastic ribs with associated 'high-riding' clavicles. A later X-ray was reported as showing interrupted posterior ribs. A tracheostomy was formed on day of life 9 given the immediate risk to the baby's airway. Further imaging of the facial bones, skull and brain showed generous CSF spaces over the cerebral convexities and also marked hypoplasia of the mandible and mid-face. The baby's middle ear cavities were shown to be completely opacified. Genetic testing eventually went on to confirm a diagnosis of cerebrocostomandibular syndrome, with the detection of a pathogenic variant of the small nuclear ribonucleoprotein polypeptide B gene.
BACKGROUND: Chorioretinopathy centralis serosa (CCS) is a common disease that leads to the loss of retinal ion/fluid homeostasis due to decompensation of the retinal pigment epithelium, resulting in fluid accumulation with detachment of the neurosensory retina and/or retinal pigment epithelium. We investigated the effect of eplerenone, a mineralocorticoid receptor inhibitor, on chronic recurrent CCS (cr-CCS).
METHODS: A retrospective study with data analysis of 17 eyes (12 patients) between 2014 - 2021 with cr-CCS in whom other methods were not effective, not applicable, or not desired, was performed. Duration of CCS was at least 12 months with at least one recurrence. Each patient received 25 mg (1st week) and 50 mg (from the 2nd week) for at least 3 months. In each case, best-corrected visual acuity and central and peripheral retinal thickness were measured by spectral-domain optical coherence tomography. Side effects were rated by the patients as "none", "mild" (noticeable but not affecting), "tolerable" (affecting but acceptable because of good effect), and "not tolerable" (then discontinuation of therapy).
RESULTS: There was no significant reduction in central or peripheral retinal thickness. A complete reduction of subretinal fluid was achieved in 5 of 17 eyes (29.4%). In 12 eyes, no effect of eplerenone could be detected, so other therapies were required. Visual acuity change was mainly dependent on the duration of CCS and the degree of photoreceptor damage. Side effects were reported by 11 patients as "none" and 1 patient as "mild" (arterial hypotension). No other side effects were observed.
CONCLUSION: The response rates of therapy with eplerenone were relatively low, and no significant effect could be demonstrated. Eplerenone should not (no longer) be routinely used in the therapy of cr-CCS.
Resonant nanostructures (RNSs) are provided in one embodiment of the present invention. RNSs may be nano- to micro-scale structures that resonate at specific frequencies through the application of an electromagnetic or acoustic stimulus. Resonant nanostructures provide new tools for diagnosing and treating disease. Resonant activation (RA) is also provided. RA may be a method of stimulating targeted chemical compounds, or nano- or micro-scale structures, in vivo and/or in vitro, to induce a response therefrom. Some RNSs include cavities that are configured to carry a payload. The resonant response of the target may include resonating, fracturing of the structure, and exposing or releasing of a payload. Targets may be changed or engage in various interactions as part of the resonant response. Such changes may include any of activating, triggering, de-activating, stimulating, attracting, repelling, joining, separating, assembling or disassembling of constituent components of a larger assembly, changing conformation, magnetizing, aligning, positioning, moving, or otherwise altering the target of the stimulus or stimuli.
Participants will be enrolled in American Association of Retired Persons' web-based driver training course, trained on how to access it, and asked to complete the course, estimated to take approximately 6-8 hours. They will also be provided with web-based access to a finance and fraud avoidance training tutorial, instructed on how to access it, and be asked to complete the course, estimated to take approximately 5-7 hours. The two courses combined are estimated to take about 15 hours.
FIELD: medicine; pharmaceuticals.SUBSTANCE: invention refers to pharmaceutical industry, namely to a drug in a solid dosage form for treating tissue helminthiasis selected from echinococcus and alveococcosis. Proposed agent contains 35–65 wt. % of copolymer of N-vinylpyrrolidone and 2-methyl-5-vinylpyridine of formula (I)as an active substance, where M monomer link of formula (II), n is 30–38 mol. % and viscosity-average molecular weight of copolymer Mis equal to 15–28 kDa, and as pharmaceutically acceptable excipients: a) 55–33.5 wt. % of at least one substance used as filler and binder selected from lactose monohydrate, microcrystalline cellulose, dibasic calcium phosphate dihydrate, isomalt, mannitol, saccharose, potato starch, corn starch, dextranes, cyclodextranes, pregelatinised starch, and at least one binder selected from purified water, polyvinylpyrrolidone and hydroxypropyl methyl cellulose; b) 10–1.5 wt. % of at least one sliding, selected from silicon colloidal dioxide, sodium stearyl fumarate, talc, stearic acid.EFFECT: invention provides a wider range of products for treating echinococcosis and alveococcosis, having less toxicity.1 cl, 4 ex, 12 tbl
PURPOSE: To obtain a skin cosmetic containing a guanidine derivative (salt) having a specific structure, capable of exhibiting excellent softening property- imparting effect to corneal layer for a long time, free from stickiness and capable of providing good feeling of use. CONSTITUTION: This cosmetic contains preferably 0.01-20wt.% of a guanidine derivative of formula I or II [A and B are each a 2-8C alkylene; D is a direct bond, CO, etc.; E is H, a lower alkyl; (m) is 1-6; (n) is 0-6; R<1> is H, a lower alkyl, etc.; (l) is 1-10; G is H, phosphate group, etc.) or its salt (preferably guanidinoethoxyethanol, guanidinopropanoic acid, etc.) as an active ingredient. The compound of formula I or II is obtained by reacting, e.g. an amine derivative such as 2-(2-aminoethoxy)ethanol with a guanidylation reagent such as cyanamide. Furthermore, the effect can moreover be enhanced by further blending the cosmetic with 0.01-10wt.% of succinic acid.
PURPOSE: To obtain a therapeutic agent, capable of raising the ceramide concentration in a neuron, suppressing the degeneration and death of the neuron and useful for diseases or disorders in the nervous system. CONSTITUTION: This suppressant for the degeneration or death of a neuron contains sphingomyelinase which is an enzyme capable of catalyzing reaction for acting on an N-acylsphingosine of the formula (R-CO is acyl), e.g. N- acetylsphingosine or sphingomyelin as a substrate and decomposing the substrate into a ceramide and phosphocholine. Diseases or disorders due to degenerating diseases and damage to the nervous system, exposure to toxic medicines and subnutrition are cited as the diseases or disorders of the nervous system. The suppressor for the degeneration or death of the neuron is orally or parenterally administered and the daily dose thereof is within the range of 5-500mg, preferably 10-100mg in the case of oral administration to an adult. The therapeutic agent is effective against Alzheimer diseases, Parkinson diseases, anticancer agential peripheral nerve neuropathies, etc.
PCT No. PCT/JP96/02890 Sec. 371 Date May 15, 1998 Sec. 102(e) Date May 15, 1998 PCT Filed Oct. 4, 1996 PCT Pub. No. WO97/17991 PCT Pub. Date May 22, 1997The present invention provides a novel method for treating acute hepatic failure comprising administering a therapeutically effective amount of human growth hormone (hGH) to a patient suffering from the acute hepatic failure as well as a novel therapeutic agent for acute hepatic failure comprising the human growth hormone as an active ingredient.
BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) is common in children undergoing cancer treatment, and significantly impacts quality of life. Clinical practice guidelines (CPGs) have been developed to guide CINV management, though many patients do not receive guideline-concordant care. Few studies have examined provider perspectives on CINV management or preferred improvement approaches, or pediatric patient perception of CINV control.
METHODS: A cross-sectional study of pediatric oncology providers was conducted at a large freestanding children's hospital. Providers completed an anonymous online survey about CINV control in patients admitted for scheduled chemotherapy, and their knowledge and utilization of CINV CPGs. A survey of English and Spanish-speaking pediatric oncology patients admitted for scheduled chemotherapy was conducted to assess CINV management, with key demographics used to understand association with perceptions and adherence to antiemetic guidelines.
RESULTS: For providers, 75% of respondents felt CINV management could be moderately or extremely improved, significantly more so by chemotherapy prescribers and pediatric medical residents than nurses. Over half of respondents did not have awareness of CINV CPGs, particularly pediatric medical residents. For patients, nausea was reported to be extremely well controlled in 44% of cases, and vomiting extremely well controlled in 50% of cases. There were no significant differences in patient-reported CINV across demographics, when considering emetogenicity of chemotherapy received, or concordance to guidelines.
CONCLUSIONS: Implementing education in this area may help to improve provider comfort, and ultimately, the patient experience. Future studies will expand upon this novel patient perception, and develop and evaluate CINV management interventions.
PURPOSE: To obtain a swelling control medicine delivery system using a crosslinked polyacid resin absorbing a therapeutic medicine therein and having a pH-dependent swelling characteristic, capable of delivering and releasing the medicine in a gastrointestinal part having a higher pH value than that of the intragastric environment and used for administering the medicine into the intestine. CONSTITUTION: A relatively high mol.wt. protein or polypeptide medicine (e.g. insulin) or therapeutic medicine is absorbed in a polyacid resin (e.g. polyacrylic acid), and a solvent is subsequently removed to prepare the polymeric swelling control medicine release composition. Therein, the medicine is absorbed in the crosslinked polyacid resin so that the composition is minimally swollen in a gastric environment without losing the efficiency of the medicine but remarkably swollen in an environment having a higher pH value than that in the gastric environment in the insoluble state to release an effective dose of the medicine therein. The composition is a system especially useful for delivering the medicine into the small intestine through the stomach.
PURPOSE: To provide a new compd. which consists of N-iodopropargyl hydantoin, which has antimicrobial activity and which is safe for animals and human bodies and used for an antimicrobial agent or the like to protect woods, coatings. fibers, leather or the like from attacks of microbes.  
     CONSTITUTION: This N-iodopropargyl hydantoin compd. having antimicrobial activity expressed by formula V or VI is obtd. by reacting a compd. expressed by formula I or formula II (e.g. 5,5-dimethylhydantoin) with propargylbromide in a solvent in the presence of a base by heating for propargylation to obtain a compd. expressed by formula III or IV (e.g. 3-(2-propynyl)-5,5-dimethyl hydantoin or the like), then adding N-iodosuccinimlde and dry acetone to prepare a uniform soln., and further adding silver nitrate to react at room temp. In formula I, A is 1-12C alkyl, benzyl, (substd.) phenyl or the like; R 1 , R 2  are H, 1-3C alkyl, (substd.)phenyl or the like. In formula III, R 3 , R 4  are H, 1-3C alkyl. 
     COPYRIGHT: (C)1994,JPO
The study will enroll approximately 33 chemotherapy-naive stage IV non-small cell lung cancer patients. Patients will receive 3-week cycles of therapy with the exception of the initial cycle where the patients will receive 4 cycles of therapy. Patients will be enrolled after EGFr expression is confirmed and the study inclusion and exclusion criteria are met. An initial dose of cetuximab will be administered prior to the initiation of chemotherapy. Thereafter, cetuximab will be infused weekly. On the first day of each cycle, a paclitaxel infusion will be administered post completion of the cetuximab infusion, immediately followed by a carboplatin infusion. Patients will receive cetuximab in combination with carboplatin and paclitaxel for two cycles or until disease progression or until the patient exhibits intolerable toxicities. Patients will be evaluated for a tumor response at the end of every two cycles of therapy and evaluated for safety throughout the study.